^
Association details:
| Biomarker: | NR3C1 overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | relacorilant (CORT125134) (GCR antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
524MO - Glucocorticoid receptor expression and activity in a phase II ovarian cancer trial of the glucocorticoid receptor modulator relacorilant in combination with nab-paclitaxel
Published date:
09/05/2022
Excerpt:
In contrast, high GR expression was associated with good response (partial or complete response) in patients receiving RELA + NP (χ2 P= 0.037). Subjects with low baseline plasma TGF-β1 (<30,000 pg/mL) treated with RELA + NP had significantly longer overall survival (OS) compared to those with high TGF-β1 (P<0.0001)... In contrast, high baseline tumor GR expression was associated with good response in patients treated with RELA + NP. Low plasma TGF-β1 predicted longer OS.
Secondary therapy:
albumin-bound paclitaxel
Trial ID:
